Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LCA-0391
- Development stage
- Preclinical
- Lead developer
- Lycia Therapeutics
- Modality
- Lysosome-Targeting Antibody Chimeras (LYTAC / CataLYTAC) → Antibody-Based Degraders → Antibody-Based Therapeutics
01
Overview
LCA-0391 is a LYTAC (Lysosome Targeting Chimera) degrader being developed by Lycia Therapeutics for the treatment of MuSK-positive (MuSK+) myasthenia gravis. It is designed to selectively target and degrade anti-muscle-specific kinase (MuSK) autoantibodies, which are pathogenic drivers of this rare autoimmune neuromuscular disease. By utilizing the LYTAC platform, LCA-0391 recruits the cation-independent mannose-6-phosphate receptor (CI-M6PR) to shuttle the extracellular autoantibodies to the lysosome for degradation, thereby reducing the circulating levels of the disease-causing antibodies. As of 2024, the program has been designated as a development candidate and is in preclinical development.
02
Targets
MuSK-Ab (Muscle-specific kinase autoantibody)IGF2R (Cation-independent mannose-6-phosphate receptor)
Beyond the preview
Go deeper on LCA-0391.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LCA-0391.